1. Home
  2. CINGW vs FPAY Comparison

CINGW vs FPAY Comparison

Compare CINGW & FPAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • FPAY
  • Stock Information
  • Founded
  • CINGW N/A
  • FPAY 2003
  • Country
  • CINGW United States
  • FPAY United States
  • Employees
  • CINGW 13
  • FPAY N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • FPAY Diversified Commercial Services
  • Sector
  • CINGW Health Care
  • FPAY Consumer Discretionary
  • Exchange
  • CINGW Nasdaq
  • FPAY Nasdaq
  • Market Cap
  • CINGW N/A
  • FPAY N/A
  • IPO Year
  • CINGW 2021
  • FPAY N/A
  • Fundamental
  • Price
  • CINGW $0.04
  • FPAY $1.60
  • Analyst Decision
  • CINGW
  • FPAY Strong Buy
  • Analyst Count
  • CINGW 0
  • FPAY 2
  • Target Price
  • CINGW N/A
  • FPAY $3.25
  • AVG Volume (30 Days)
  • CINGW N/A
  • FPAY 161.4K
  • Earning Date
  • CINGW N/A
  • FPAY 03-31-2025
  • Dividend Yield
  • CINGW N/A
  • FPAY N/A
  • EPS Growth
  • CINGW N/A
  • FPAY N/A
  • EPS
  • CINGW N/A
  • FPAY N/A
  • Revenue
  • CINGW N/A
  • FPAY $134,563,007.00
  • Revenue This Year
  • CINGW N/A
  • FPAY $25.78
  • Revenue Next Year
  • CINGW N/A
  • FPAY $6.46
  • P/E Ratio
  • CINGW N/A
  • FPAY N/A
  • Revenue Growth
  • CINGW N/A
  • FPAY 24.46
  • 52 Week Low
  • CINGW N/A
  • FPAY $0.97
  • 52 Week High
  • CINGW N/A
  • FPAY $2.37
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • FPAY 51.49
  • Support Level
  • CINGW N/A
  • FPAY $1.50
  • Resistance Level
  • CINGW N/A
  • FPAY $1.80
  • Average True Range (ATR)
  • CINGW 0.00
  • FPAY 0.12
  • MACD
  • CINGW 0.00
  • FPAY 0.02
  • Stochastic Oscillator
  • CINGW 0.00
  • FPAY 57.45

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: